Overview
Atara Biotherapeutics develops off-the-shelf, allogeneic T-cell immunotherapies targeting cancer, autoimmune diseases, and viral conditions using its EBV T-cell platform. Key pipeline assets include tab-cel® (tabelecleucel) in Phase 3 for EBV+ post-transplant lymphoproliferative disease and ATA3219, an anti-CD19 CAR T therapy. The company has commercialization partnerships, such as with Pierre Fabre for tab-cel® in Europe, Middle East, Africa, and select emerging markets.
Frequently asked questions
- What are Atara Biotherapeutics' key therapeutic capabilities?
- Atara specializes in off-the-shelf allogeneic T-cell immunotherapies for cancer, autoimmune diseases, and viral conditions, leveraging an EBV T-cell platform with assets like tab-cel® for EBV+ PTLD and ATA3219 anti-CD19 CAR T.
- What is the regulatory status of Atara's lead product tab-cel®?
- Tab-cel® (tabelecleucel) is in Phase 3 for EBV+ post-transplant lymphoproliferative disease and earlier stages for other EBV-associated malignancies; Atara is the first to receive approval for an allogeneic T-cell immunotherapy.
- In which geographies does Atara commercialize its therapies?
- Atara retains rights in North America, Asia Pacific, and Latin America for tab-cel®; Pierre Fabre handles commercialization in Europe, Middle East, Africa, and select emerging markets, with Atara providing manufacturing services.